Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07201129 · ClinicalTrials.gov registry record · Phase 3

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

A Phase 3 study of Lupus Erythematosus, Systemic and Nephritis, Lupus, sponsored by Viatris Innovation.

Recruiting
Registry status
Phase 3
Development phase
300
Enrollment target
6
Study locations

NCT07201129 is a Phase 3 study of Lupus Erythematosus, Systemic and Nephritis, Lupus that is actively recruiting participants, run by Viatris Innovation. The registered enrollment target is 300 participants, above the 193-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (55% higher). The trial reports 6 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07201129, a Phase 3 study of Lupus Erythematosus, Systemic and Nephritis, Lupus, is actively recruiting participants, sponsored by Viatris Innovation.

RECRUITING
Registry status
Phase 3
Development phase
300 participants
Enrollment target
6
Study locations

Study Summary

The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.

Conditions Studied

Lupus Erythematosus, Systemic Nephritis, Lupus

Interventions

  • DRUG Placebo
  • DRUG Cenerimod

Study Locations (6)

Florida

  • SouthCoast Research Center - Miami
  • Allied Biomedical Research Institute - Miami
  • ProfessionalResearchCenter INC - Miami
  • San Marcus Research Clinic, Inc. - Miami Lakes

Texas

  • Rheumatology Care Center, PLLC - Bellaire
  • Northwest Houston Arthritis - Houston

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2026-02-09
Est. Completion 2030-02
Phase Phase 3

Sponsor

Viatris Innovation

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07201129

The ClinicalTrials.gov registry entry for NCT07201129 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 193-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (55% higher). The listed sponsor is Viatris Innovation, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07201129 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT07201129 about?

NCT07201129 is a clinical study titled "A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment". The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cen...

What is the current status of trial NCT07201129?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-02-09. Estimated completion is 2030-02.

What conditions does trial NCT07201129 study?

This clinical trial studies the following conditions: Lupus Erythematosus, Systemic, Nephritis, Lupus.

What interventions are being tested in trial NCT07201129?

The interventions under investigation include: Placebo (DRUG), Cenerimod (DRUG).

Who is sponsoring clinical trial NCT07201129?

This trial is sponsored by Viatris Innovation, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07201129 being conducted?

This trial has 6 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus Erythematosus, Systemic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lupus Erythematosus, Systemic

All registered trials for this condition

Nephritis, Lupus

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.